| Bioactivity | Lu-AAZTA-NI-PSMA-093 is a bivalent radiopharmaceutical agent for prostate cancer, that enhances tumor uptake and retention by combining a hypoxia-sensitive nitroimidazole (NI) moiety with a targeting moiety to PSMA[1]. |
| Formula | C63H82LuN14O26 |
| Molar Mass | 1626.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Luo Y, et al., 68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer. J Med Chem. 2024 Aug 8;67(15):13491-13506. |
Lu-AAZTA-NI-PSMA-093
CAS: F: C63H82LuN14O26 W: 1626.37
Lu-AAZTA-NI-PSMA-093 is a bivalent radiopharmaceutical agent for prostate cancer, that enhances tumor uptake and retenti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.